Top-Rated StocksTop-RatedNASDAQ:ANAB AnaptysBio (ANAB) Stock Price, News & Analysis $37.06 -0.17 (-0.46%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$36.89▼$38.8550-Day Range$22.89▼$37.2352-Week Range$13.36▼$38.85Volume288,204 shsAverage Volume329,370 shsMarket Capitalization$1.01 billionP/E RatioN/ADividend YieldN/APrice Target$51.89 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get AnaptysBio alerts: Email Address AnaptysBio MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.90 Rating ScoreUpside/Downside40.0% Upside$51.89 Price TargetShort InterestBearish21.39% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.60Based on 20 Articles This WeekInsider TradingSelling Shares$484,824 Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($6.26) to ($6.99) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.41 out of 5 starsMedical Sector746th out of 936 stocksPharmaceutical Preparations Industry348th out of 436 stocks 3.5 Analyst's Opinion Consensus RatingAnaptysBio has received a consensus rating of Moderate Buy. The company's average rating score is 2.90, and is based on 9 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageAnaptysBio has only been the subject of 3 research reports in the past 90 days.Read more about AnaptysBio's stock forecast and price target. Previous Next 0.0 Short Interest Percentage of Shares Shorted21.39% of the float of AnaptysBio has been sold short.Short Interest Ratio / Days to CoverAnaptysBio has a short interest ratio ("days to cover") of 14.8, which indicates bearish sentiment.Change versus previous monthShort interest in AnaptysBio has recently increased by 6.58%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldAnaptysBio does not currently pay a dividend.Dividend GrowthAnaptysBio does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ANAB. Previous Next 3.1 News and Social Media Coverage News SentimentAnaptysBio has a news sentiment score of 0.60. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 20 news articles for AnaptysBio this week, compared to 3 articles on an average week.Search Interest5 people have searched for ANAB on MarketBeat in the last 30 days. MarketBeat Follows7 people have added AnaptysBio to their MarketBeat watchlist in the last 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, AnaptysBio insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $484,824.00 in company stock.Percentage Held by Insiders33.70% of the stock of AnaptysBio is held by insiders. A high percentage of insider ownership can be a sign of company health.Read more about AnaptysBio's insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for AnaptysBio are expected to decrease in the coming year, from ($6.26) to ($6.99) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of AnaptysBio is -6.04, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of AnaptysBio is -6.04, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAnaptysBio has a P/B Ratio of 11.16. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about AnaptysBio's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Unstoppable Prosperity“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.You can find out what they are by clicking here now. About AnaptysBio Stock (NASDAQ:ANAB)AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis. The company also focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has a collaboration and license agreement with GlaxoSmithKline, Inc. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.Read More ANAB Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ANAB Stock News HeadlinesJuly 20, 2024 | insidertrades.comAnaptysBio, Inc. (NASDAQ:ANAB) Insider Sells $52,500.00 in StockJuly 18, 2024 | insidertrades.comInsider Selling: AnaptysBio, Inc. (NASDAQ:ANAB) Director Sells 10,000 Shares of StockJuly 26, 2024 | Weiss Ratings (Ad)Nvidia’s Quiet $1 Trillion PivotNvidia recently added $277 billion in market cap … IN ONE DAY.July 26 at 6:14 AM | americanbankingnews.comAnaptysBio (NASDAQ:ANAB) Sets New 12-Month High at $37.50July 24 at 5:39 AM | americanbankingnews.comBrokers Offer Predictions for AnaptysBio, Inc.'s Q2 2024 Earnings (NASDAQ:ANAB)July 23 at 4:22 PM | msn.comHC Wainwright & Co. Initiates Coverage of AnaptysBio (ANAB) with Buy RecommendationJuly 23 at 7:28 AM | sg.finance.yahoo.comAnaptysBio, Inc. (ANAB) stock historical prices & data – Yahoo FinanceJuly 23 at 5:22 AM | americanbankingnews.comAnaptysBio (NASDAQ:ANAB) Receives New Coverage from Analysts at HC WainwrightJuly 26, 2024 | WealthPress (Ad)This TSLA short trade is on a nine win hot streakMost Tesla Shareholders are disappointed in the stock's performance in 2024. Year to date, it's down 30%... And things don’t seem to be getting better. That said, one professional trader has found a way to turn Tesla’s demise into a flurry of opportunity… In fact, he has not lost a single trade on Tesla this year. As of this mailing he’s 9 for 9 with incredible wins under his belt. Just see for yourself.July 22, 2024 | benzinga.comAnaptysBio Investigational Arthritis Drug Might Have Better Efficacy Profile Than Eli Lilly's: AnalystJuly 22, 2024 | markets.businessinsider.comAnaptysBio’s Promising Pipeline and Rosnilimab’s Best-in-Class Potential Justify Buy RatingJuly 20, 2024 | americanbankingnews.comAnaptysBio (NASDAQ:ANAB) Upgraded at JPMorgan Chase & Co.July 20, 2024 | americanbankingnews.comAnaptysBio (NASDAQ:ANAB) Hits New 52-Week High at $35.98July 19, 2024 | americanbankingnews.comHollings Renton Sells 10,000 Shares of AnaptysBio, Inc. (NASDAQ:ANAB) StockJuly 18, 2024 | americanbankingnews.comShort Interest in AnaptysBio, Inc. (NASDAQ:ANAB) Grows By 5.2%July 18, 2024 | americanbankingnews.comAnaptysBio, Inc. (NASDAQ:ANAB) Receives $46.38 Consensus Target Price from BrokeragesJuly 8, 2024 | seekingalpha.comAnaptysBio: Interesting Prospects, But Wait For The Dip (Rating Downgrade)May 22, 2024 | finance.yahoo.comIndustry Analysts Just Upgraded Their AnaptysBio, Inc. (NASDAQ:ANAB) Revenue Forecasts By 16%See More Headlines Receive ANAB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for AnaptysBio and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/09/2024Today7/26/2024Next Earnings (Estimated)8/05/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ANAB CUSIPN/A CIK1370053 Webwww.anaptysbio.com Phone(858) 362-6295FaxN/AEmployees100Year Founded2005Price Target and Rating Average Stock Price Target$51.89 High Stock Price Target$80.00 Low Stock Price Target$21.00 Potential Upside/Downside+40.0%Consensus RatingModerate Buy Rating Score (0-4)2.90 Research Coverage10 Analysts Profitability EPS (Most Recent Fiscal Year)($6.14) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-163,620,000.00 Net Margins-711.17% Pretax Margin-711.19% Return on Equity-161.40% Return on Assets-35.07% Debt Debt-to-Equity RatioN/A Current Ratio11.53 Quick Ratio11.53 Sales & Book Value Annual Sales$17.16 million Price / Sales59.00 Cash FlowN/A Price / Cash FlowN/A Book Value$3.32 per share Price / Book11.16Miscellaneous Outstanding Shares27,320,000Free Float18,112,000Market Cap$1.01 billion OptionableOptionable Beta-0.25 Social Links 7 Energy Stocks to Buy and Hold ForeverDo you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.Get This Free Report Key ExecutivesMr. Daniel R. Faga (Age 44)President, CEO & Director Comp: $867.12kMr. Eric J. Loumeau (Age 61)Chief Legal Officer Comp: $685.59kDr. James Newman Topper M.D. (Age 62)Ph.D., Advisor Comp: $86.5kDr. Paul F. Lizzul FAAD (Age 49)M.B.A., M.D., M.P.H., Ph.D., Chief Medical Officer Comp: $656.36kMr. Dennis M. Mulroy (Age 69)Chief Financial Officer Comp: $448.81kMs. Beth MuellerSenior Vice President of Human ResourcesDr. Martin Dahl Ph.D.Senior Vice President of ResearchMr. Benjamin StoneChief Business OfficerMr. Douglas A. Rich M.B.A. (Age 55)Senior Vice President of CMC Ms. Monique Da SilvaSenior Vice President of Corporate AffairsMore ExecutivesKey CompetitorsAlbireo PharmaNASDAQ:ALBOArcellxNASDAQ:ACLXXenon PharmaceuticalsNASDAQ:XENEMerusNASDAQ:MRUSADMA BiologicsNASDAQ:ADMAView All CompetitorsInsiders & InstitutionsBank of New York Mellon CorpBought 10,423 shares on 7/26/2024Ownership: 0.273%Assenagon Asset Management S.A.Bought 84,795 shares on 7/18/2024Ownership: 1.122%Paul F LizzulSold 1,500 sharesTotal: $52,500.00 ($35.00/share)Hollings RentonSold 10,000 sharesTotal: $306,400.00 ($30.64/share)Dennis M FentonSold 1,950 sharesTotal: $45,181.50 ($23.17/share)View All Insider TransactionsView All Institutional Transactions ANAB Stock Analysis - Frequently Asked Questions How have ANAB shares performed this year? AnaptysBio's stock was trading at $21.42 at the beginning of the year. Since then, ANAB shares have increased by 73.0% and is now trading at $37.06. View the best growth stocks for 2024 here. How were AnaptysBio's earnings last quarter? AnaptysBio, Inc. (NASDAQ:ANAB) released its quarterly earnings results on Thursday, May, 9th. The biotechnology company reported ($1.64) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.54) by $0.10. The biotechnology company earned $7.18 million during the quarter, compared to analyst estimates of $4.55 million. AnaptysBio had a negative net margin of 711.17% and a negative trailing twelve-month return on equity of 161.40%. When did AnaptysBio IPO? AnaptysBio (ANAB) raised $60 million in an initial public offering on Thursday, January 26th 2017. The company issued 4,000,000 shares at $14.00-$16.00 per share. Credit Suisse and Stifel served as the underwriters for the IPO and JMP Securities and Wedbush PacGrow were co-managers. Who are AnaptysBio's major shareholders? AnaptysBio's top institutional shareholders include Assenagon Asset Management S.A. (1.12%), Bank of New York Mellon Corp (0.27%) and Concourse Financial Group Securities Inc.. Insiders that own company stock include Ecor1 Capital, Llc, Paul F Lizzul, Eric J Loumeau, Hollings Renton, Dennis M Fenton, Dennis Mulroy and Hamza Suria. View institutional ownership trends. How do I buy shares of AnaptysBio? Shares of ANAB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of AnaptysBio own? Based on aggregate information from My MarketBeat watchlists, some other companies that AnaptysBio investors own include bluebird bio (BLUE), ImmunoGen (IMGN), NVIDIA (NVDA), CRISPR Therapeutics (CRSP), Amarin (AMRN), Editas Medicine (EDIT) and Illumina (ILMN). This page (NASDAQ:ANAB) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredWe recommended Nvidia in 2016, now we’re recommending this…The AI boom is just getting started. And the real wealth has still to be made…Porter & Company | SponsoredNEW AI developed by trader who won 1,129% (in 2 days)Earlier this year one legendary trader captured a 1,129% win (in just 2 days) ... LIVE in front of thousands o...Monument Traders Alliance | SponsoredBreaking News: Elon Musk Invents New Type of A.I. (Shocking)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock (June 12) This $2 trillion D.C. shock i...Timothy Sykes | SponsoredGrab a pen and write down this ticker - here's whyA megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | SponsoredWhy is NVDA stumbling?July is historically the best month of the year for U.S. stocks. So why are everyone’s favorite tech stocks...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding AnaptysBio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share AnaptysBio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
